|
US8067237B2
(en)
|
2005-12-13 |
2011-11-29 |
President And Fellows Of Harvard College |
Scaffolds for cell transplantation
|
|
AU2011311904B2
(en)
|
2010-10-06 |
2016-02-25 |
President And Fellows Of Harvard College |
Injectable, pore-forming hydrogels for materials-based cell therapies
|
|
DK2838515T3
(da)
|
2012-04-16 |
2020-02-24 |
Harvard College |
Mesoporøse siliciumdioxidsammensætninger til modulering af immunresponser
|
|
WO2013185052A1
(en)
|
2012-06-08 |
2013-12-12 |
Aduro Biotech |
Compostions and methods for cancer immunotherapy
|
|
EA201590396A1
(ru)
*
|
2012-12-13 |
2015-12-30 |
Адуро Биотек, Инк. |
Композиция, содержащая циклические пуриновые динуклеотиды с определенной стереохимией, и способ ее получения и применения
|
|
EP2991655B1
(en)
|
2013-04-29 |
2024-04-10 |
Memorial Sloan Kettering Cancer Center |
Compositions and methods for altering second messenger signaling
|
|
WO2014179760A1
(en)
|
2013-05-03 |
2014-11-06 |
The Regents Of The University Of California |
Cyclic di-nucleotide induction of type i interferon
|
|
EP3653637A1
(en)
*
|
2013-05-18 |
2020-05-20 |
Aduro BioTech, Inc. |
Compositions and methods for activating "stimulator of interferon genes"-dependent signalling
|
|
US9549944B2
(en)
*
|
2013-05-18 |
2017-01-24 |
Aduro Biotech, Inc. |
Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling
|
|
US10176292B2
(en)
|
2013-07-31 |
2019-01-08 |
Memorial Sloan-Kettering Cancer Center |
STING crystals and modulators
|
|
EP3049442A4
(en)
|
2013-09-26 |
2017-06-28 |
Costim Pharmaceuticals Inc. |
Methods for treating hematologic cancers
|
|
EP3071209A4
(en)
*
|
2013-11-19 |
2017-08-16 |
The University of Chicago |
Use of sting agonist as cancer treatment
|
|
WO2015109391A1
(en)
|
2014-01-24 |
2015-07-30 |
Children's Hospital Of Eastern Ontario Research Institute Inc. |
Smc combination therapy for the treatment of cancer
|
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
|
US10682400B2
(en)
|
2014-04-30 |
2020-06-16 |
President And Fellows Of Harvard College |
Combination vaccine devices and methods of killing cancer cells
|
|
JP6462006B2
(ja)
|
2014-06-04 |
2019-01-30 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ |
Ｓｔｉｎｇのモジュレーターとしての環式ジヌクレオチド
|
|
CA2960824A1
(en)
|
2014-09-13 |
2016-03-17 |
Novartis Ag |
Combination therapies of alk inhibitors
|
|
MA41044A
(fr)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
|
|
PE20171067A1
(es)
|
2014-10-14 |
2017-07-24 |
Novartis Ag |
Moleculas de anticuerpo que se unen a pd-l1 y usos de las mismas
|
|
US11058758B2
(en)
*
|
2014-11-20 |
2021-07-13 |
National Institutes Of Biomedical Innovation, Health And Nutrition |
TH1-inducing adjuvant comprising combination of different nucleic acid adjuvants, and use of same
|
|
CN107148424B
(zh)
*
|
2014-12-16 |
2021-01-08 |
凯拉治疗股份公司 |
用于诱导细胞因子的环状二核苷酸
|
|
GB201501462D0
(en)
*
|
2015-01-29 |
2015-03-18 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
|
EP3250250A4
(en)
*
|
2015-01-30 |
2019-05-22 |
President and Fellows of Harvard College |
PERITUMORAL AND INTRATUMORAL MATERIALS FOR CANCER THERAPY
|
|
US10130663B2
(en)
|
2015-02-11 |
2018-11-20 |
The John Hopkins University |
Bacteria over-expressing c-di-AMP and therapeutic methods
|
|
WO2016145102A1
(en)
|
2015-03-10 |
2016-09-15 |
Aduro Biotech, Inc. |
Compositions and methods for activating "stimulator of interferon gene" -dependent signalling
|
|
JP7094533B2
(ja)
|
2015-04-10 |
2022-07-04 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
免疫細胞捕捉デバイスおよびその製造および使用方法
|
|
EP3603661A3
(en)
|
2015-04-22 |
2020-04-01 |
CureVac AG |
Rna containing composition for treatment of tumor diseases
|
|
JP6878405B2
(ja)
*
|
2015-07-29 |
2021-05-26 |
ノバルティス アーゲー |
Ｐｄ−１に対する抗体分子を含む組み合わせ治療
|
|
EP3878465A1
(en)
|
2015-07-29 |
2021-09-15 |
Novartis AG |
Combination therapies comprising antibody molecules to tim-3
|
|
EP3317301B1
(en)
|
2015-07-29 |
2021-04-07 |
Novartis AG |
Combination therapies comprising antibody molecules to lag-3
|
|
CN106692967A
(zh)
*
|
2015-08-12 |
2017-05-24 |
聊城市奥润生物医药科技有限公司 |
环二核苷酸cGAMP联合PD1的抗体（Nivolumab）在制备抗肿瘤药物中的应用
|
|
MX2018001814A
(es)
|
2015-08-13 |
2018-05-07 |
Merck Sharp & Dohme |
Compuestos dinucleotidos ciclicos como agonistas del estimulador de genes de interferon.
|
|
US11453697B1
(en)
|
2015-08-13 |
2022-09-27 |
Merck Sharp & Dohme Llc |
Cyclic di-nucleotide compounds as sting agonists
|
|
CN106540255A
(zh)
*
|
2015-09-18 |
2017-03-29 |
聊城市奥润生物医药科技有限公司 |
环二核苷酸cGAMP联合贝伐珠单抗在抗肿瘤中的应用
|
|
US10906930B2
(en)
|
2015-10-28 |
2021-02-02 |
Chinook Therapeutics, Inc. |
Compositions and methods for activating “stimulator of interferon gene”-dependent signalling
|
|
MA44334A
(fr)
|
2015-10-29 |
2018-09-05 |
Novartis Ag |
Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
|
|
MX363780B
(es)
|
2015-12-03 |
2019-04-03 |
Glaxosmithkline Ip Dev Ltd |
Dinucleótidos de purina cíclica como moduladores del estimulador de los genes de interferón.
|
|
SG11201804957VA
(en)
|
2015-12-16 |
2018-07-30 |
Gritstone Oncology Inc |
Neoantigen identification, manufacture, and use
|
|
WO2017106740A1
(en)
*
|
2015-12-16 |
2017-06-22 |
Aduro Biotech, Inc. |
Methods for identifying inhibitors of "stimulator of interferon gene"-dependent interferon production
|
|
JP2019503349A
(ja)
|
2015-12-17 |
2019-02-07 |
ノバルティス アーゲー |
Ｐｄ−１に対する抗体分子およびその使用
|
|
CA3009001A1
(en)
|
2016-01-11 |
2017-07-20 |
Universitat Zurich |
Immune-stimulating humanized monoclonal antibodies against human interleukin-2, and fusion proteins thereof
|
|
MY194058A
(en)
|
2016-01-11 |
2022-11-10 |
Innate Tumor Immunity Inc |
Cyclic dinucleotides for treating conditions associated with sting activity such as cancer
|
|
US10723756B2
(en)
|
2016-01-11 |
2020-07-28 |
Innate Tumor Immunity Inc. |
Cyclic dinucleotides for treating conditions associated with STING activity such as cancer
|
|
CN106544319A
(zh)
*
|
2016-01-24 |
2017-03-29 |
聊城市奥润生物医药科技有限公司 |
一种用于刺激树突状细胞成熟的组合物及其用于刺激树突状细胞成熟的方法
|
|
CN115531609A
(zh)
|
2016-02-06 |
2022-12-30 |
哈佛学院校长同事会 |
重塑造血巢以重建免疫
|
|
AU2017233068C1
(en)
*
|
2016-03-18 |
2023-05-25 |
Immune Sensor, Llc |
Cyclic di-nucleotide compounds and methods of use
|
|
CN106540256A
(zh)
*
|
2016-03-27 |
2017-03-29 |
聊城市奥润生物医药科技有限公司 |
环二核苷酸-脂质体偶联单克隆抗体在抗肿瘤中的应用
|
|
NZ745957A
(en)
|
2016-04-07 |
2020-07-31 |
Glaxosmithkline Ip Dev Ltd |
Heterocyclic amides useful as protein modulators
|
|
AU2017247806B2
(en)
|
2016-04-07 |
2019-11-14 |
Glaxosmithkline Intellectual Property Development Limited |
Heterocyclic amides useful as protein modulators
|
|
SG11201809082WA
(en)
|
2016-04-19 |
2018-11-29 |
Innate Tumor Immunity Inc |
Nlrp3 modulators
|
|
US10533007B2
(en)
|
2016-04-19 |
2020-01-14 |
Innate Tumor Immunity, Inc. |
NLRP3 modulators
|
|
US10696985B1
(en)
|
2016-06-06 |
2020-06-30 |
Vanderbilt University |
Reversibly crosslinked endosomolytic polymer vesicles for cytosolic drug delivery
|
|
US11098077B2
(en)
|
2016-07-05 |
2021-08-24 |
Chinook Therapeutics, Inc. |
Locked nucleic acid cyclic dinucleotide compounds and uses thereof
|
|
WO2018009652A1
(en)
*
|
2016-07-06 |
2018-01-11 |
Sperovie Biosciences, Inc. |
Compounds, compositions, and methods for the treatment of disease
|
|
AU2017293781B2
(en)
*
|
2016-07-06 |
2022-12-22 |
Invox Pharma Limited |
Compounds, compositions, and methods for the treatment of disease
|
|
EP3484448A4
(en)
|
2016-07-13 |
2020-04-01 |
President and Fellows of Harvard College |
MIMETIC SCAFFOLDS OF CELLS HAVING ANTIGEN AND METHODS OF PREPARING AND USING THEM
|
|
NL2017267B1
(en)
|
2016-07-29 |
2018-02-01 |
Aduro Biotech Holdings Europe B V |
Anti-pd-1 antibodies
|
|
NL2017270B1
(en)
|
2016-08-02 |
2018-02-09 |
Aduro Biotech Holdings Europe B V |
New anti-hCTLA-4 antibodies
|
|
EP3497119A1
(en)
|
2016-08-09 |
2019-06-19 |
Aarhus Universitet |
Modulation of ifi16 and sting activity
|
|
KR102497742B1
(ko)
|
2016-08-30 |
2023-02-10 |
다나-파버 캔서 인스티튜트 인크. |
약물 전달 조성물 및 그의 용도
|
|
WO2018053508A1
(en)
|
2016-09-19 |
2018-03-22 |
The University Of North Carolina At Chapel Hill |
Methods and compositions for inducing an immune response
|
|
US10537590B2
(en)
*
|
2016-09-30 |
2020-01-21 |
Boehringer Ingelheim International Gmbh |
Cyclic dinucleotide compounds
|
|
CR20190168A
(es)
|
2016-10-04 |
2019-05-17 |
Merck Sharp & Dohme |
Compuestos de benzo[b]tiofeno como agonistas de sting
|
|
WO2018065360A1
(de)
|
2016-10-07 |
2018-04-12 |
Biolog Life Science Institute Forschungslabor Und Biochemica-Vertrieb Gmbh |
Benzimidazolhaltige cyclische dinukleotide, verfahren zu deren herstellung und ihre verwendung zur aktivierung von stimulator von interferongenen (sting)-abhängigen signalwegen
|
|
CA3038810A1
(en)
|
2016-10-11 |
2018-04-19 |
The Governors Of The University Of Alberta |
Hepatitis c virus immunogenic compositions and methods of use thereof
|
|
JOP20170188A1
(ar)
|
2016-11-25 |
2019-01-30 |
Janssen Biotech Inc |
ثنائي النوكليوتيدات الحلقية كمنبهات ستينغ (sting)
|
|
JP2018090562A
(ja)
*
|
2016-12-01 |
2018-06-14 |
武田薬品工業株式会社 |
環状ジヌクレオチド
|
|
JOP20170192A1
(ar)
|
2016-12-01 |
2019-01-30 |
Takeda Pharmaceuticals Co |
داي نوكليوتيد حلقي
|
|
JP2020503303A
(ja)
*
|
2016-12-20 |
2020-01-30 |
メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． |
がんの処置のための環状ジヌクレオチドｓｔｉｎｇアゴニスト
|
|
WO2018118664A1
(en)
*
|
2016-12-20 |
2018-06-28 |
Merck Sharp & Dohme Corp. |
Combinations of pd-1 antagonists and cyclic dinucleotide sting agonists for cancer treatment
|
|
US11492367B2
(en)
|
2017-01-27 |
2022-11-08 |
Janssen Biotech, Inc. |
Cyclic dinucleotides as sting agonists
|
|
EP3573717B1
(en)
|
2017-01-27 |
2021-07-28 |
Janssen Biotech, Inc. |
Cyclic dinucleotides as sting agonists
|
|
SG11201906969PA
(en)
|
2017-02-01 |
2019-08-27 |
Modernatx Inc |
Immunomodulatory therapeutic mrna compositions encoding activating oncogene mutation peptides
|
|
US20200055883A1
(en)
|
2017-02-17 |
2020-02-20 |
Eisai R&D Management Co., Ltd. |
Cyclic di-nucleotides derivative for the treatment of cancer
|
|
JP2018131427A
(ja)
*
|
2017-02-17 |
2018-08-23 |
国立研究開発法人理化学研究所 |
免疫細胞の制御技術
|
|
TWI674261B
(zh)
|
2017-02-17 |
2019-10-11 |
美商英能腫瘤免疫股份有限公司 |
Nlrp3 調節劑
|
|
WO2018156625A1
(en)
|
2017-02-21 |
2018-08-30 |
Board Of Regents,The University Of Texas System |
Cyclic dinucleotides as agonists of stimulator of interferon gene dependent signalling
|
|
CN106727331B
(zh)
*
|
2017-03-13 |
2022-02-01 |
杭州星鳌生物科技有限公司 |
免疫脂质体-环二核苷酸的组成、制备方法及其在抗肿瘤中的应用
|
|
AU2018240199A1
(en)
|
2017-03-20 |
2019-10-17 |
Genocea Biosciences, Inc. |
Treatment methods
|
|
JOP20190218A1
(ar)
|
2017-03-22 |
2019-09-22 |
Boehringer Ingelheim Int |
مركبات ثنائية النيوكليوتيدات حلقية معدلة
|
|
KR20240135066A
(ko)
|
2017-04-13 |
2024-09-10 |
사이로파 비.브이. |
항-sirp 알파 항체
|
|
SG11201909516VA
(en)
|
2017-04-14 |
2019-11-28 |
Tollnine Inc |
Immunomodulating polynucleotides, antibody conjugates thereof, and methods of their use
|
|
AR111651A1
(es)
|
2017-04-28 |
2019-08-07 |
Novartis Ag |
Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
|
|
AR113224A1
(es)
*
|
2017-04-28 |
2020-02-19 |
Novartis Ag |
Conjugados de anticuerpo que comprenden un agonista de sting
|
|
UY37695A
(es)
|
2017-04-28 |
2018-11-30 |
Novartis Ag |
Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
|
|
US11466047B2
(en)
|
2017-05-12 |
2022-10-11 |
Merck Sharp & Dohme Llc |
Cyclic di-nucleotide compounds as sting agonists
|
|
WO2018210279A1
(zh)
*
|
2017-05-16 |
2018-11-22 |
科济生物医药（上海）有限公司 |
Toll样受体激动剂与免疫效应细胞的联用
|
|
WO2018229715A1
(en)
|
2017-06-16 |
2018-12-20 |
Novartis Ag |
Compositions comprising anti-cd32b antibodies and methods of use thereof
|
|
WO2018237173A1
(en)
|
2017-06-22 |
2018-12-27 |
Novartis Ag |
ANTIBODY MOLECULES DIRECTED AGAINST CD73 AND CORRESPONDING USES
|
|
MA49457A
(fr)
|
2017-06-22 |
2020-04-29 |
Novartis Ag |
Molécules d'anticorps se liant à cd73 et leurs utilisations
|
|
CA3069524A1
(en)
|
2017-07-14 |
2019-01-17 |
Innate Tumor Immunity, Inc. |
Nlrp3 modulators
|
|
EP3431484A1
(en)
*
|
2017-07-21 |
2019-01-23 |
Ludwig-Maximilians-Universität München |
A fluorescent cyclic dinucleotide and its use in methods of identifying substances having an ability to modulate the cgas/sting pathway
|
|
JP7186764B2
(ja)
*
|
2017-07-28 |
2022-12-09 |
ブリストル－マイヤーズ スクイブ カンパニー |
抗癌剤としての環状ジヌクレオチド
|
|
MA49773A
(fr)
|
2017-08-04 |
2021-04-21 |
Merck Sharp & Dohme |
Combinaisons d'antagonistes de pd-1 et d'agonistes de sting benzo[b
|
|
EP3661498A4
(en)
|
2017-08-04 |
2021-04-21 |
Merck Sharp & Dohme Corp. |
BENZO [B] THIOPHEN STING ANTAGONISTS FOR CANCER TREATMENT
|
|
CN111263767B
(zh)
|
2017-08-30 |
2023-07-18 |
北京轩义医药科技有限公司 |
作为干扰素基因调节剂的刺激剂的环状二核苷酸
|
|
US11638716B2
(en)
|
2017-08-31 |
2023-05-02 |
F-star Therapeutics, Inc. |
Compounds, compositions, and methods for the treatment of disease
|
|
KR102674630B1
(ko)
*
|
2017-08-31 |
2024-06-11 |
브리스톨-마이어스 스큅 컴퍼니 |
항암제로서의 시클릭 디뉴클레오티드
|
|
WO2019046498A1
(en)
*
|
2017-08-31 |
2019-03-07 |
Bristol-Myers Squibb Company |
CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS
|
|
PL3678668T3
(pl)
|
2017-09-08 |
2024-06-03 |
The Board Of Trustees Of The Leland Stanford Junior University |
Inhibitory enpp1 i ich zastosowanie w leczeniu nowotworu
|
|
WO2019051488A1
(en)
|
2017-09-11 |
2019-03-14 |
Sperovie Biosciences, Inc. |
COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISEASE
|
|
US11707531B2
(en)
|
2017-09-11 |
2023-07-25 |
F-star Therapeutics, Inc. |
Compounds, compositions, and methods for the treatment of disease
|
|
CA3077337A1
(en)
|
2017-10-05 |
2019-04-11 |
Glaxosmithkline Intellectual Property Development Limited |
Modulators of stimulator of interferon genes (sting)
|
|
WO2019069269A1
(en)
|
2017-10-05 |
2019-04-11 |
Glaxosmithkline Intellectual Property Development Limited |
INTERFERON GENE STIMULATOR MODULATORS USEFUL IN THE TREATMENT OF HIV
|
|
JP7227237B2
(ja)
|
2017-10-10 |
2023-02-21 |
グリットストーン バイオ インコーポレイテッド |
ホットスポットを利用した新生抗原の特定
|
|
US20210040205A1
(en)
|
2017-10-25 |
2021-02-11 |
Novartis Ag |
Antibodies targeting cd32b and methods of use thereof
|
|
AU2018364708A1
(en)
|
2017-11-10 |
2020-05-21 |
Takeda Pharmaceutical Company Limited |
Sting modulator compounds, and methods of making and using
|
|
EA038805B1
(ru)
*
|
2017-11-21 |
2021-10-21 |
Такеда Фармасьютикал Компани Лимитед |
Циклические динуклеотиды в качестве агонистов sting (стимулятор генов интерферона)
|
|
CN111630602A
(zh)
|
2017-11-22 |
2020-09-04 |
磨石肿瘤生物技术公司 |
减少新抗原的接合表位呈递
|
|
WO2019104353A1
(en)
*
|
2017-11-27 |
2019-05-31 |
Children's Medical Center Corporation |
Stimulator of interferon genes (sting) ligands and uses thereof
|
|
EP3724205B1
(en)
*
|
2017-12-15 |
2022-06-22 |
Janssen Biotech, Inc. |
Cyclic dinucleotides as sting agonists
|
|
WO2019123340A1
(en)
|
2017-12-20 |
2019-06-27 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
|
|
EP3727401A4
(en)
|
2017-12-20 |
2022-04-06 |
Merck Sharp & Dohme Corp. |
CYCLIC DINUCLEOTIDE COMPOUNDS USED AS STING AGONISTS
|
|
CN111511754B
(zh)
|
2017-12-20 |
2023-09-12 |
捷克共和国有机化学与生物化学研究所 |
活化sting转接蛋白的具有膦酸酯键的2’3’环状二核苷酸
|
|
JP7230035B2
(ja)
*
|
2018-01-04 |
2023-02-28 |
アカデミア シニカ |
治療を強化するための細胞会合免疫アジュバントならびに同アジュバントを含むキットおよび処方物
|
|
JP2021512144A
(ja)
*
|
2018-01-26 |
2021-05-13 |
ザ リージェンツ オブ ザ ユニヴァーシティ オブ カリフォルニアＴｈｅ Ｒｅｇｅｎｔｓ ｏｆ ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ ｏｆ Ｃａｌｉｆｏｒｎｉａ |
環状ジヌクレオチドアジュバント含有結核ワクチンの鼻腔内送達
|
|
RU2020128830A
(ru)
|
2018-02-02 |
2022-03-03 |
Новартис Аг |
Комбинация агониста sting и il-15/il-15rа для лечения рака
|
|
EP3749681A1
(en)
*
|
2018-02-06 |
2020-12-16 |
STipe Therapeutics ApS |
Modulation of p62 and sting activity
|
|
TW201946650A
(zh)
|
2018-03-12 |
2019-12-16 |
美商詹森藥物公司 |
針對腹內感染之疫苗
|
|
CN110272462B
(zh)
*
|
2018-03-15 |
2023-03-10 |
南开大学 |
制备化合物的方法
|
|
JP7519297B2
(ja)
|
2018-03-23 |
2024-07-19 |
ロンザ セールス アーゲー |
Ｓｔｉｎｇアゴニストを含む細胞外小胞
|
|
EP3774834A1
(en)
|
2018-03-27 |
2021-02-17 |
Boehringer Ingelheim International GmbH |
Cyclic dinucleotide compounds containing 2-aza-hypoxanthine or 6h-pytazolo[1,5-d][1,2,4]triazin-7-one as sting agonists
|
|
EP3774833A1
(en)
|
2018-03-27 |
2021-02-17 |
Boehringer Ingelheim International GmbH |
Modified cyclic dinucleotide compounds
|
|
TWI793294B
(zh)
|
2018-04-03 |
2023-02-21 |
美商默沙東有限責任公司 |
Sting促效劑化合物
|
|
US11702430B2
(en)
|
2018-04-03 |
2023-07-18 |
Merck Sharp & Dohme Llc |
Aza-benzothiophene compounds as STING agonists
|
|
US11874276B2
(en)
|
2018-04-05 |
2024-01-16 |
Dana-Farber Cancer Institute, Inc. |
STING levels as a biomarker for cancer immunotherapy
|
|
TWI833744B
(zh)
|
2018-04-06 |
2024-03-01 |
捷克科學院有機化學與生物化學研究所 |
3'3'-環二核苷酸
|
|
TWI818007B
(zh)
*
|
2018-04-06 |
2023-10-11 |
捷克科學院有機化學與生物化學研究所 |
2'3'-環二核苷酸
|
|
TW202005654A
(zh)
|
2018-04-06 |
2020-02-01 |
捷克科學院有機化學與生物化學研究所 |
２，２，─環二核苷酸
|
|
KR102711180B1
(ko)
|
2018-04-25 |
2024-09-26 |
인네이트 튜머 이뮤니티, 인코포레이티드 |
Nlrp3 조정제
|
|
CN108310378A
(zh)
*
|
2018-04-28 |
2018-07-24 |
杭州星鳌生物科技有限公司 |
一类新型免疫联体抗肿瘤创新药物的制备及其应用
|
|
US20190359645A1
(en)
|
2018-05-03 |
2019-11-28 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
2'3'-cyclic dinucleotides comprising carbocyclic nucleotide
|
|
GB201807924D0
(en)
|
2018-05-16 |
2018-06-27 |
Ctxt Pty Ltd |
Compounds
|
|
WO2019232244A2
(en)
|
2018-05-31 |
2019-12-05 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
|
AU2019277679A1
(en)
|
2018-06-01 |
2020-12-24 |
Eisai R&D Management Co., Ltd. |
Methods for the treatment of bladder cancer
|
|
US20210260093A1
(en)
*
|
2018-06-20 |
2021-08-26 |
Yale University |
RIG-I Agonists and Treatments Using Same
|
|
TW202014408A
(zh)
|
2018-07-03 |
2020-04-16 |
美商Ｉｆｍ Ｄｕｅ有限公司 |
用於治療與sting活性相關之病症的化合物及組合物
|
|
WO2020010155A1
(en)
|
2018-07-03 |
2020-01-09 |
Ifm Due, Inc. |
Compounds and compositions for treating conditions associated with sting activity
|
|
JP7340591B2
(ja)
*
|
2018-07-11 |
2023-09-07 |
アクティム・セラピューティクス・インコーポレイテッド |
遺伝子操作された免疫刺激性細菌菌株およびその使用
|
|
EP3837014B1
(en)
|
2018-08-16 |
2022-10-19 |
Innate Tumor Immunity, Inc. |
Imidazo[4,5-c]quinoline derived nlrp3-modulators
|
|
JP2021534180A
(ja)
|
2018-08-16 |
2021-12-09 |
イネイト・テューマー・イミュニティ・インコーポレイテッドInnate Tumor Immunity, Inc. |
置換４−アミノ−１Ｈ−イミダゾ［４，５−ｃ］キノリン化合物およびその製造の改良法
|
|
EP3837015B1
(en)
|
2018-08-16 |
2024-02-14 |
Innate Tumor Immunity, Inc. |
Imidazo[4,5-c]quinoline derived nlrp3-modulators
|
|
TWI717804B
(zh)
|
2018-08-16 |
2021-02-01 |
日商衛材R&D企管股份有限公司 |
化合物之鹽及其晶體
|
|
WO2020041720A1
(en)
|
2018-08-24 |
2020-02-27 |
Codiak Biosciences, Inc. |
Extracellular vesicles targeting dendritic cells and uses thereof
|
|
US20220008549A1
(en)
|
2018-09-06 |
2022-01-13 |
Daiichi Sankyo Company, Limited |
Novel cyclic dinucleotide derivative and antibody-drug conjugate thereof
|
|
WO2020049534A1
(en)
|
2018-09-07 |
2020-03-12 |
Novartis Ag |
Sting agonist and combination therapy thereof for the treatment of cancer
|
|
WO2020059895A1
(ko)
*
|
2018-09-17 |
2020-03-26 |
주식회사 큐라티스 |
스팅 작용자를 포함하는 면역항원보강제 및 백신 조성물
|
|
AU2019344398B2
(en)
*
|
2018-09-21 |
2022-09-22 |
Shanghai De Novo Pharmatech Co., Ltd. |
Cyclic dinucleotide analogue, pharmaceutical composition thereof, and application
|
|
AU2019371206A1
(en)
|
2018-10-29 |
2021-05-27 |
Venenum Biodesign, LLC |
Novel sting agonists
|
|
JP2022512897A
(ja)
|
2018-10-29 |
2022-02-07 |
ジェノセア バイオサイエンシーズ， インコーポレイテッド |
治療方法
|
|
US11110106B2
(en)
|
2018-10-29 |
2021-09-07 |
Venenum Biodesign, LLC |
Sting agonists for treating bladder cancer and solid tumors
|
|
WO2020092633A1
(en)
|
2018-10-30 |
2020-05-07 |
Vanderbilt University |
Graft copolymers, methods of forming graft copolymers, and methods of use thereof
|
|
EP3873938A1
(en)
|
2018-10-31 |
2021-09-08 |
Novartis AG |
Dc-sign antibody conjugates comprising sting agonists
|
|
US11596692B1
(en)
|
2018-11-21 |
2023-03-07 |
Incyte Corporation |
PD-L1/STING conjugates and methods of use
|
|
US20220024964A1
(en)
*
|
2018-12-07 |
2022-01-27 |
Merck Sharp & Dohme Corp. |
Cyclic Di-Nucleotide Compounds as STING Agonists
|
|
WO2020117624A1
(en)
*
|
2018-12-07 |
2020-06-11 |
Merck Sharp & Dohme Corp. |
Cyclic di-nucleotide compounds as sting agonists
|
|
WO2020117625A1
(en)
*
|
2018-12-07 |
2020-06-11 |
Merck Sharp & Dohme Corp. |
Cyclic di-nucleotide compounds as sting agonists
|
|
EP3901161A4
(en)
*
|
2019-01-10 |
2022-03-23 |
Nankai University |
CYCLIC DINUCLEOTIDE PRODRUG MOLECULE, METHOD OF PRODUCTION THEREOF AND APPLICATION THEREOF
|
|
WO2020150116A1
(en)
|
2019-01-14 |
2020-07-23 |
Innate Tumor Immunity, Inc. |
Nlrp3 modulators
|
|
EP3911417B1
(en)
|
2019-01-14 |
2022-10-26 |
Innate Tumor Immunity, Inc. |
Heterocyclic nlrp3 modulators , for use in the treatment of cancer
|
|
JP7335341B2
(ja)
|
2019-01-14 |
2023-08-29 |
イネイト・テューマー・イミュニティ・インコーポレイテッド |
Ｎｌｒｐ３モジュレーター
|
|
US20220089571A1
(en)
|
2019-01-14 |
2022-03-24 |
Innate Tumor Immunity, Inc. |
Nlrp3 modulators
|
|
WO2020150417A2
(en)
|
2019-01-17 |
2020-07-23 |
Ifm Due, Inc. |
Compounds and compositions for treating conditions associated with sting activity
|
|
US10998091B2
(en)
|
2019-02-07 |
2021-05-04 |
Sandeep Patil |
Systems for monitoring compliance with a patch dosage regimen and methods of using the same
|
|
US12024709B2
(en)
|
2019-02-27 |
2024-07-02 |
Actym Therapeutics, Inc. |
Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
|
|
JP7350872B2
(ja)
*
|
2019-03-07 |
2023-09-26 |
インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール，ヴイ．ヴイ．アイ． |
３’３’－環状ジヌクレオチドおよびそのプロドラッグ
|
|
AU2020231201A1
(en)
*
|
2019-03-07 |
2021-08-26 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
2'3'-cyclic dinucleotides and prodrugs thereof
|
|
EP3935065A1
(en)
|
2019-03-07 |
2022-01-12 |
Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. |
3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
|
|
AU2020240075A1
(en)
|
2019-03-18 |
2021-10-14 |
Janssen Pharmaceuticals, Inc. |
Methods of producing bioconjugates of e. coli o-antigen polysaccharides, compositions thereof, and methods of use thereof
|
|
WO2020191082A1
(en)
|
2019-03-18 |
2020-09-24 |
Janssen Pharmaceuticals, Inc. |
Bioconjugates of e. coli o-antigen polysaccharides, methods of production thereof, and methods of use thereof
|
|
WO2020191369A1
(en)
|
2019-03-21 |
2020-09-24 |
Codiak Biosciences, Inc. |
Process for preparing extracellular vesicles
|
|
SG11202109587TA
(en)
|
2019-03-21 |
2021-10-28 |
Codiak Biosciences Inc |
Extracellular vesicle conjugates and uses thereof
|
|
CN114080232A
(zh)
|
2019-03-21 |
2022-02-22 |
科迪亚克生物科学公司 |
用于疫苗递送的细胞外囊泡
|
|
WO2020205688A1
(en)
|
2019-04-04 |
2020-10-08 |
Merck Sharp & Dohme Corp. |
Inhibitors of histone deacetylase-3 useful for the treatment of cancer, inflammation, neurodegeneration diseases and diabetes
|
|
TW202104214A
(zh)
|
2019-04-05 |
2021-02-01 |
英商葛蘭素史密斯克藍智慧財產發展有限公司 |
化合物
|
|
MA55805A
(fr)
|
2019-05-03 |
2022-03-09 |
Flagship Pioneering Innovations V Inc |
Métodes de modulation de l'activité immunitaire
|
|
JP2022531899A
(ja)
|
2019-05-09 |
2022-07-12 |
アリゴス セラピューティクス インコーポレイテッド |
Ｓｔｉｎｇモジュレータとしての修飾環状ジヌクレオシド化合物
|
|
MX2021013657A
(es)
|
2019-05-10 |
2022-02-21 |
Takeda Pharmaceuticals Co |
Conjugados de anticuerpo y farmaco.
|
|
JP2022535743A
(ja)
|
2019-05-29 |
2022-08-10 |
アイエフエム デュー インコーポレイテッド |
Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物
|
|
WO2021003445A1
(en)
|
2019-07-03 |
2021-01-07 |
Codiak Biosciences, Inc. |
Extracellular vesicles targeting t cells and uses thereof
|
|
CN114340680A
(zh)
|
2019-07-05 |
2022-04-12 |
坦博公司 |
反式环辛烯生物正交剂及在癌症和免疫疗法中的用途
|
|
GB201910304D0
(en)
|
2019-07-18 |
2019-09-04 |
Ctxt Pty Ltd |
Compounds
|
|
GB201910305D0
(en)
|
2019-07-18 |
2019-09-04 |
Ctxt Pty Ltd |
Compounds
|
|
BR112022001931A2
(pt)
|
2019-08-02 |
2022-06-21 |
Mersana Therapeutics Inc |
Derivados de bis-[n-((5-carbamoil)-1h-benzo[d]imidazol-2-il)-pirazol-5-carboxamida e compostos relacionados como agonistas de sting (estimulador de genes de interferon) para o tratamento de câncer
|
|
US12098212B2
(en)
|
2019-08-12 |
2024-09-24 |
Purinomia Biotech, Inc. |
Methods and compositions for promoting and potentiating T-cell mediated immune responses through ADCC targeting of CD39 expressing cells
|
|
WO2021041532A1
(en)
|
2019-08-26 |
2021-03-04 |
Dana-Farber Cancer Institute, Inc. |
Use of heparin to promote type 1 interferon signaling
|
|
EP3785719A1
(en)
*
|
2019-08-28 |
2021-03-03 |
Helmholtz-Zentrum für Infektionsforschung GmbH |
New use of cyclic dinucleotides
|
|
WO2021062058A1
(en)
|
2019-09-25 |
2021-04-01 |
Codiak Biosciences, Inc. |
Sting agonist comprising exosomes for treating neuroimmunological disorders
|
|
MX2022003570A
(es)
|
2019-09-25 |
2022-07-11 |
Codiak Biosciences Inc |
Composiciones de vesícula extracelular.
|
|
US20220395465A1
(en)
|
2019-09-25 |
2022-12-15 |
Codiak Biosciences, Inc. |
Sting agonist comprising exosomes combined with il-12 displaying exosomes for treating a tumour
|
|
US20230103726A1
(en)
|
2019-09-25 |
2023-04-06 |
Codiak Biosciences, Inc. |
Methods of producing extracellular vesicles
|
|
MX2022004061A
(es)
|
2019-10-02 |
2022-07-19 |
Janssen Vaccines & Prevention Bv |
Peptidos de estafilococo y metodos de uso.
|
|
WO2021074695A1
(en)
|
2019-10-16 |
2021-04-22 |
Avacta Life Sciences Limited |
PD-L1 INHIBITOR - TGFβ INHIBITOR BISPECIFIC DRUG MOIETIES.
|
|
US20230074558A1
(en)
|
2019-12-06 |
2023-03-09 |
Mersana Therapeutics, Inc. |
Dimeric compounds as sting agonists
|
|
US20230348458A1
(en)
|
2020-01-10 |
2023-11-02 |
Innate Tumor Immunity, Inc. |
Nlrp3 modulators
|
|
KR20220128372A
(ko)
|
2020-01-16 |
2022-09-20 |
얀센 파마슈티칼즈, 인코포레이티드 |
Fimh 돌연변이체, 이를 갖는 조성물 및 이의 용도
|
|
WO2021174091A1
(en)
|
2020-02-28 |
2021-09-02 |
Tallac Therapeutics, Inc. |
Transglutaminase-mediated conjugation
|
|
CA3168368A1
(en)
|
2020-03-06 |
2021-09-10 |
Masayuki Ishizaki |
Antibody-drug conjugate including novel cyclic dinucleotide derivative
|
|
WO2021184017A1
(en)
|
2020-03-13 |
2021-09-16 |
Codiak Biosciences, Inc. |
Extracellular vesicles for treating neurological disorders
|
|
JP2023518414A
(ja)
|
2020-03-20 |
2023-05-01 |
コディアック バイオサイエンシーズ， インコーポレイテッド |
治療のための細胞外小胞
|
|
TW202200136A
(zh)
|
2020-04-10 |
2022-01-01 |
日商小野藥品工業股份有限公司 |
癌治療方法
|
|
US11857618B2
(en)
|
2020-04-17 |
2024-01-02 |
Emory University |
Boosting immunogenicity of vaccines using saponins and agonists of the intracellular stimulator of interferon genes pathway
|
|
CN115835856A
(zh)
|
2020-05-13 |
2023-03-21 |
麻省理工学院 |
聚合物微装置的组合物以及其在癌症免疫疗法中的用途
|
|
WO2021237100A1
(en)
|
2020-05-21 |
2021-11-25 |
Codiak Biosciences, Inc. |
Methods of targeting extracellular vesicles to lung
|
|
CN116056765A
(zh)
|
2020-08-07 |
2023-05-02 |
坦伯公司 |
反式环辛烯生物正交剂及在癌症和免疫疗法中的用途
|
|
TW202227479A
(zh)
|
2020-09-02 |
2022-07-16 |
日商第一三共股份有限公司 |
新穎內－β－Ｎ－乙醯葡萄糖胺苷酶
|
|
WO2022055929A1
(en)
|
2020-09-08 |
2022-03-17 |
The Board Of Regents Of The University Of Texas System |
Polyvalent sting activating compositions and uses thereof
|
|
AU2021342797B2
(en)
|
2020-09-17 |
2024-02-08 |
Janssen Pharmaceuticals, Inc. |
Multivalent vaccine compositions and uses thereof
|
|
CA3193107A1
(en)
|
2020-09-23 |
2022-03-31 |
Codiak Biosciences, Inc. |
Process for preparing extracellular vesicles
|
|
WO2022066883A1
(en)
|
2020-09-23 |
2022-03-31 |
Codiak Biosciences, Inc. |
Extracellular vesicles comprising kras antigens and uses thereof
|
|
CA3192470A1
(en)
|
2020-09-23 |
2022-03-31 |
Tim SOOS |
Methods of producing extracellular vesicles
|
|
US20240241020A1
(en)
|
2020-09-23 |
2024-07-18 |
Lonza Sales Ag |
Process for preparing extracellular vesicles
|
|
US20220111028A1
(en)
|
2020-10-14 |
2022-04-14 |
Boehringer Ingelheim International Gmbh |
Combination Of A STING Agonist And A Complex Comprising A Cell Penetrating Peptide, A Cargo And A TLR Peptide Agonist
|
|
EP3984535A1
(en)
|
2020-10-16 |
2022-04-20 |
Albert-Ludwigs-Universität Freiburg |
Nlrp3 activators for use in the treatment of infectious diseases or cancer by activating nlrp3 inflammasome
|
|
AU2021363267A1
(en)
|
2020-10-20 |
2023-06-22 |
Tyligand Bioscience (Shanghai) Limited |
Multifunctional cyclic dinucleotide and use thereof
|
|
US20230390409A1
(en)
|
2020-10-30 |
2023-12-07 |
Avacta Life Sciences Limited |
Fap-activated serum extended half-life therapeutic conjugates
|
|
AU2021374958A1
(en)
|
2020-11-09 |
2023-06-22 |
Takeda Pharmaceutical Company Limited |
Antibody drug conjugates
|
|
JP2023554396A
(ja)
|
2020-12-17 |
2023-12-27 |
トラスティーズ オブ タフツ カレッジ |
Ｆａｐ活性化ラジオセラノスティクスおよび関連する使用
|
|
CA3207841A1
(en)
|
2021-01-12 |
2022-07-21 |
Janssen Pharmaceuticals, Inc |
Fimh mutants, compositions therewith and use thereof
|
|
TW202241454A
(zh)
|
2021-02-01 |
2022-11-01 |
日商第一三共股份有限公司 |
抗體－免疫賦活化劑共軛物之新穎製造方法
|
|
TW202304504A
(zh)
|
2021-04-01 |
2023-02-01 |
美商詹森藥物公司 |
大腸桿菌ｏ１８生物軛合物之生產
|
|
WO2022223622A1
(en)
|
2021-04-20 |
2022-10-27 |
Institut Curie |
Compositions and methods for use in immunotherapy
|
|
WO2022223619A1
(en)
|
2021-04-20 |
2022-10-27 |
Institut Curie |
Compositions and methods for use in immunotherapy
|
|
WO2022234003A1
(en)
|
2021-05-07 |
2022-11-10 |
Avacta Life Sciences Limited |
Cd33 binding polypeptides with stefin a protein
|
|
US20220313724A1
(en)
*
|
2021-05-17 |
2022-10-06 |
Highlight Therapeutics, S.L. |
Compositions for intratumoral administration and related methods
|
|
WO2023056468A1
(en)
|
2021-09-30 |
2023-04-06 |
Codiak Biosciences, Inc. |
Extracellular vesicle comprising cholesterol tagged sting-agonist
|
|
TW202334196A
(zh)
|
2021-10-07 |
2023-09-01 |
英商阿法克塔生命科學有限公司 |
Pd-l1結合多肽
|
|
CN114106140A
(zh)
*
|
2021-11-23 |
2022-03-01 |
哈尔滨医科大学附属肿瘤医院 |
一种表达特定sting异构体、细胞系、制备方法、用途
|
|
WO2023154799A1
(en)
|
2022-02-14 |
2023-08-17 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Combination immunotherapy for treating cancer
|
|
IL315341A
(en)
|
2022-03-02 |
2024-10-01 |
Daiichi Sankyo Co Ltd |
A method for producing a molecule containing Fc
|
|
WO2023218243A1
(en)
|
2022-05-12 |
2023-11-16 |
Avacta Life Sciences Limited |
Lag-3/pd-l1 binding fusion proteins
|
|
WO2024211577A1
(en)
|
2023-04-05 |
2024-10-10 |
Massachusetts Institute Of Technology |
Hybrid polymeric systems and methods of use thereof
|